Ads
related to: diffusion pharmaceuticals inc- Contact Us
Discover How Our Team Can Help You
Every Phase of the Way! Contact Us
- Oral Dose Drug eBook
Download Our Free eBook on the Oral
Dosage Drug Delivery Market
- Parenteral Drug eBook
Get Exclusive Insights & Explore
the Parenteral Drug Delivery Market
- Oral Drug Development
Deliver Your Molecule in the
Preferred Drug Formulation
- Contact Us
Search results
Results From The WOW.Com Content Network
By David Bautz, PhD NASDAQ:DFFN READ THE FULL DFFN RESEARCH REPORT Business Update Evaluating Strategic Opportunities On November 14, 2022, Diffusion Pharmaceuticals, Inc. (NASDAQ:DFFN) provided ...
Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) is a publicly traded biotechnology and drug development company based in Charlottesville, Virginia, U.S. [2] It was co-founded in 2001 by American life sciences entrepreneur David Kalergis and University of Virginia Chemical Engineering Professor John L. Gainer. [2]
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
David Kalergis. David Kalergis (born December 9, 1948) is an American life sciences entrepreneur and the co-founder and chair of Atelerix Life Sciences Inc., a Charlottesville, Virginia, U.S.-based biotechnology and pharmaceutical company developing novel treatments for the reversal of opioid induced respiratory depression. [1]
John Gainer. John L. Gainer (born July 19, 1938) is an American chemical engineer and co-founder and former chief scientific officer of Diffusion Pharmaceuticals, a biotechnology and pharmaceutical company based in Charlottesville, Virginia, U.S. [1] Professor Gainer retired from his position as Chief Science Officer of Diffusion Pharmaceuticals in March, 2020. [2]
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
Several approaches have been taken to address tumor hypoxia. Some companies tried to develop drugs that are activated in hypoxic environments (Novacea, Inc. Proacta, Inc, Convert Pharmaceuticals, and Threshold Pharmaceuticals, Inc), while others are currently seeking to reduce tumor hypoxia (Diffusion Pharmaceuticals, Inc. and NuvOx Pharma, LLC).